Company intelligence / Profile preview

Kolon Group

Gwacheon-si, Gyeonggi-do, South Koreakolon.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Kolon Pharma has a diverse pipeline with both commercialized drugs and early-stage assets. The company’s strengths include respiratory science and dermatology. Following its merger with Plat Bio in 2023, it has expanded into oncology drug development using advanced clinical translational platforms. Some marketed products rank among the top three by market share domestically. No recent pivotal trial results were found.

Therapeutic areas: PulmonologyDermatologyOther
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Invossa

Commercial

Indications: Osteoarthritis

Partnerships

Collaborations with top-tier pharmaceutical firms for specialty medications across multiple domains including pulmonology and dermatology.Joint R&D projects with global pharma companies targeting markets such as Korea and China post-merger with Plat Bio

Beyond the preview

Go deeper on Kolon Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kolon Group.

Explore the full profile